AstraZeneca’s Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

 AstraZeneca’s Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

AstraZeneca’s Fasenra Receives Orphan Drug Designation (ODD) For Hypereosinophilic Syndrome (HES)

Shots:

  • The FDA’s ODD for Fasenra follows its evaluation in P-II study assessing Fasenra vs PBO @12 weeks in patients with high level of eosinophils in blood and tissues 
  • The P-II study demonstrated meeting its 1EP with depleted blood eosinophils at week 12 and is conducted by United States NIH with Astrazeneca, published in H2’19
  • Fasenra (benralizumab) is a mAb, binds with IL-5 receptor on eosinophils and has received FDA’s ODD for eosinophilic granulomatosis with polyangiitis (EGPA) in Nov,2018 and is approved for severe eosinophilic asthma in the US, EU and Japan

Click here read full press release/ article | Ref: AstraZeneca | Image:  Rte

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post